Today, VistaGen Therapeutics announced that it has received
broader intellectual property protection for its stem cell technology platform.
The United States Patent and Trademark Office recently issued a notice of
allowance (NOA) for U.S. Patent Application 12/836,275, entitled “Cell
populations enriched for endoderm cells.” The NOA extends VistaGen
Therapeutics’ intellectual property portfolio for pluripotent stem cell culture
systems that produce human cells of the endoderm lineage, including liver,
lung, pancreas, parathyroid, and thyroid cells.
When issued, this patent will be complementary to U.S.
Patent Nos. 7,763,466, 8,512,957 and 8,143,009, both of which are exclusively
licensed by VistaGen Therapeutics from the Ichan School of Medicine at Mount
Sinai in New York.
“This patent allowance is another critical step in extending
intellectual property protection for our stem cell technology platform.
LiverSafe 3D™, one of our core assay systems for drug rescue, in particular
stands to benefit greatly from this broader intellectual property protection,”
stated Shawn K. Singh, VistaGen’s Chief Executive Officer.
“In addition to expanding the scope of our drug rescue
opportunities, this patent allowance and our world-class differentiation
expertise put VistaGen in a unique position to pursue potential stem cell
research collaborations related to liver biology and drug metabolism assays, as
well as pancreatic beta-islet cells for drug and regenerative cell therapy for
diabetes,” said Ralph Snodgrass, Ph.D., VistaGen’s President and Chief
Scientific Officer.
VistaGen Therapeutics’ reception of the NOA builds on other
recent developments that could be promising for the company. VistaGen
Therapeutics recently joined the Cardiac Research Safety Consortium, a driving
force in public-private research that evaluates the cardiac safety of medical
products. The Cardiac Research Safety Consortium draws upon expertise from key
stakeholders in the industrial, academic, and governmental sectors for data
sharing and expertise. It was launched as a public-private partnership in 2006
through an FDA Critical Path Initiative Memorandum of Understanding with Duke
University. With this new membership, VistaGen Therapeutics can benefit from
new, key partnerships in the future.
The company’s LiverSafe 3D™ technology is a human liver
cell-based biological assay system capable of predicting liver toxicity and
metabolism issues in drug candidates that have been stop-gapped for development
due to any unexpected liver problems arising during development. This
technology is complemented by VistaGen Therapeutics’ other technology,
CardioSafe 3D™, another biological assay that is useful in predicting in vivo
cardiac effects, both toxic and nontoxic, of promising new drug candidates long
before they are tested in humans.
More information about VistaGen Therapeutics, its
developments, and its potentially revolutionary innovations for the
biotechnological space can be found at www.vistagen.com.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment